https://scholars.lib.ntu.edu.tw/handle/123456789/595739
標題: | Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate | 作者: | Chang, Huai-Lung Wen, Wan-Hsin CHIEN-NAN LEE Chiu, Yu-En CHUN-JEN LIU Chang, Mei-Hwei Lin, Lung-Huang HUEY-LING CHEN |
關鍵字: | antiviral agents; hepatitis B virus; infectious disease transmission; maternal-foetal relations; pregnancy | 公開日期: | 2022 | 出版社: | WILEY | 卷: | 29 | 期: | 2 | 起(迄)頁: | 107 | 來源出版物: | Journal of Viral Hepatitis | 摘要: | Tenofovir disoproxil fumarate (TDF) is the preferred treatment to prevent mother-to-infant transmission in highly viremic HBV-infected women. Data on hepatitis B surface antigen (HBsAg) levels in pregnant women are lacking. We aimed to investigate prepartum and postpartum HBsAg kinetics and its correlation with HBV DNA in pregnant women. HBV-infected mothers with HBV DNA ≥7.5 log10 IU/ml were tested for HBsAg and HBV DNA from baseline to 6 months postpartum. Of the 186 pregnant women with comparable baseline HBsAg and HBV DNA, 101 received TDF from the third trimester until 1 month postpartum. At delivery, TDF group had mildly lower HBsAg (4.32 ± 0.47 vs. 4.54 ± 0.35 log10 IU/ml, p = .0004) and markedly lower HBV DNA (4.26 ± 0.97 vs. 8.11 ± 0.70 log10 IU/ml, p < .0001) than the control group. In the TDF group, mean reduction of HBsAg and HBV DNA from baseline to delivery were 0.22 ± 0.38 and 3.96 ± 0.93 log10 IU/ml. HBsAg reduction had a positive correlation (r = .309; p = .0017) with HBV DNA reduction, and was predictive of HBV DNA reduction ≥3 log10 IU/ml (area under the receiver operating characteristic curve, 0.67; 95% confidence interval, 0.50-0.82). At 6 months postpartum, TDF and control group had comparable HBsAg and HBV DNA. In conclusion, HBsAg decreased slightly at delivery in pregnant women receiving TDF. For monitoring the effect of antiviral therapy during pregnancy, HBV DNA is a better marker than HBsAg. Our data provided valuable information regarding monitoring HBV-infected pregnant women using antiviral therapy. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/595739 | ISSN: | 1352-0504 1365-2893 |
DOI: | 10.1111/jvh.13628 | SDG/關鍵字: | antivirus agent; hepatitis B surface antigen; tenofovir; virus DNA; chronic hepatitis B; female; genetics; hepatitis B; Hepatitis B virus; human; infant; kinetics; pregnancy; pregnancy complication; pregnant woman; prevention and control; vertical transmi |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。